Search

everythinglearnresearchcommunity

for

Search:↓

Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Medications improve quality of life for men with lower urinary tract symptoms.

These medications for BPH have known risks and may have new side effects.

Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.

There is no link between hair loss and prostate enlargement.

Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.

High serum DHT levels can help diagnose PCOS.

COVID-19 worsens urinary symptoms in men with benign prostatic hyperplasia, requiring careful treatment management.

Patients follow treatment well, but many change medicines; good information helps compliance.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

BPH is common in older men and often occurs with other age-related health issues.

High uric acid can cause health issues, so managing it with lifestyle changes is important.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

These medications for BPH have known risks and may have new side effects.

Tamsulosin is a cost-effective treatment for BPH symptoms.

Finasteride may reduce prostate cancer risk.

A 17-year-old female with adrenogenital syndrome produces very high levels of androgens, which prevent complete feminization despite high estrogen doses.

5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.

CEC levels may be a useful marker for predicting prostate cancer progression.

Erectile dysfunction is linked to marital issues in patients with benign prostatic hyperplasia.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.

PCPA induces hypersexual behavior in male rats regardless of age or castration status.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.